Mission

Durable, personalized immunotherapy in HCC requires precisio level of peptide-MHC-TCR interactions. PeptideXme integrates multi-omics discovery, structural immunology, and functional T-cell modulation to convert transient immune activation into durable, precision-guided anti-tumor immunity.

Team

Scientific Advisory Board

Prof. Philipp Kaldis

Liver metabolism & HCC Oncology

Prof. Ernesto Guccione

Epigenetic & Cancer

A

Advisor 1

HCC Clinical Oncology

A

Advisor 2

Cancer Immunotherapy

A

Advisor 3

Structural Immunology

Contact

Emaillina.zhao@med.lu.se
Phone+46 737768101
AddressMalmö, SE 214 28, Sweden